Inclusion Criteria:

1. Have given written informed consent, prior to pre-study screening, with the
understanding that consent may be withdrawn at any time without prejudice.

2. A histological diagnosis of nasopharyngeal cancer (NPC) must have been established at
some time and the investigator must review and confirm the diagnosis prior to
randomization.

3. Loco-regional advanced NPC UICC/AJCC Stages IIB, III, IVA or IVB.

4. No evidence of distant metastases in the staging work up at diagnosis.

5. Must have detectable plasma EBV-DNA (> 0 copies/ml) at 6-8 weeks after completion of
primary RT or chemo-RT

6. No clinical evidence of persistent loco-regional disease after primary treatment

7. Performance status of ECOG grade 0 or 1.

8. Patients must have adequate organ and marrow function as defined below:

leukocytes >3,000/L; absolute neutrophil count >1,500/L; platelets >100,000/L; total
bilirubin <1.5 X institutional upper limit of normal; AST(SGOT)/ALT(SGPT) <2.5 X
institutional upper limit of normal; Creatinine clearance > 50 ml/min

9. At least 18 years of age, of either sex.

10. If female, must be either (i) post-menopausal or surgically sterilized, or (ii) use a
hormonal contraceptive, intra-uterine device, diaphragm with spermicide for the
duration of the study and must be neither pregnant nor breast-feeding.

Exclusion Criteria:

1. Hypercalcaemia: calcium >= 2.7 mmol/L (10.8 mg/dL).

2. Second primary malignancy (except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin).

3. More that 12 weeks after completion of primary radiotherapy.

4. Had received prior adjuvant chemotherapy.

5. Other serious concomitant systemic disorders incompatible with the study (at the
discretion of the investigator).

6. Have serious active infection.

7. Patients with peripheral or ototoxicity with a grade of greater than 2.

8. Pregnant or lactating female subjects and subjects with reproductive potential not
implementing adequate contraceptive measures.